SLN
Silence Therapeutics Plc
stockNASDAQADR
silence therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence's proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 11.20 | 2026-09-28 | -4.87% | 0.398 |
| 1M | 14.59 | 2026-09-04 | -26.97% | 1.483 |
| 3M | 10.58 | 2026-07-06 | +0.71% | 0.706 |
| 6M | 5.80 | 2026-04-06 | +83.71% | 2.175 |
| 1Y | 5.19 | 2025-10-06 | +105.30% | 1.479 |
| 2Y | 18.64 | 2024-10-04 | -42.84% | — |
| 5Y | 21.08 | 2021-10-06 | -49.45% | 0.738 |
Silence Therapeutics Plc (NASDAQ:SLN) stock price today is $10.66, and today's volume is 973,327. SLN is down 0.514% today. The 30 day average volume is 813,348. SLN market cap is $662.25M with 62.15M shares outstanding.